Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America

Volumn 25, Issue 6, 2011, Pages 1135-1161

  Grimwade, David ^a   Mrózek, Krzysztof ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Cytogenetics; Diagnosis; Prognosis

Indexed keywords

ARSENIC TRIOXIDE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CORE BINDING FACTOR; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; FLT3 LIGAND; ISOCITRATE DEHYDROGENASE; MIXED LINEAGE LEUKEMIA PROTEIN; MYOSIN HEAVY CHAIN; NUCLEOPHOSMIN; NUCLEOPORIN 98; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; CANCER CLASSIFICATION; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 16Q; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CYTOGENETICS; DIAGNOSTIC VALUE; DNA DETERMINATION; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HEMATOPOIESIS; HIGH RISK POPULATION; KARYOTYPE; MONOSOMY 7; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

CHROMOSOME ABERRATIONS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 81255170298     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.018     Document Type: Review

References (172)

1. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973, 16(2):109-112.
2. Rowley J.D., Golomb H.M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977, 1(8010):549-550.
3. Caspersson T., Zech L., Johansson C. Differential binding of alkylating fluorochromes in human chromosomes. Exp Cell Res 1970, 60(3):315-319.
4. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971, 2(7731):971-972.
5. Mitelman F, Johansson B, Mertens F, editors, Mitelman database of chromosome aberrations and gene fusions in cancer. 2011. Available: Accessed August 2, 2011. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
6. Mrózek K., Heinonen K., Bloomfield C.D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14(1):19-47.
7. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14(3):497-529.
8. Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18(2):115-136.
9. Smith M.L., Hills R.K., Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011, 25(1):39-51.
10. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon (France). S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
11. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
12. de Thé H., Chomienne C., Lanotte M., et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990, 347(6293):558-561.
13. Borrow J., Goddard A.D., Sheer D., et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990, 249(4976):1577-1580.
14. Goddard A.D., Borrow J., Freemont P.S., et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991, 254(5036):1371-1374.
15. Brown N.J., Ramalho M., Pedersen E.W., et al. PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?. Front Biosci 2009, 14:1684-1707.
16. Grimwade D., Biondi A., Mozziconacci M.-J., et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000, 96(4):1297-1308.
17. Chen Z., Brand N.J., Chen A., et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993, 12(3):1161-1167.
18. Redner R.L., Rush E.A., Faas S., et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996, 87(3):882-886.
19. Wells R.A., Catzavelos C., Kamel-Reid S. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997, 17(1):109-113.
20. Kondo T., Mori A., Darmanin S., et al. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica 2008, 93(9):1414-1416.
21. Yamamoto Y., Tsuzuki S., Tsuzuki M., et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 2010, 116(20):4274-4283.
22. Catalano A., Dawson M.A., Somana K., et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007, 110(12):4073-4076.
23. Arnould C., Philippe C., Bourdon V., et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999, 8(9):1741-1749.
24. Grimwade D., Mistry A.R., Solomon E., et al. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res 2010, 145:219-235.
25. Licht J.D., Chomienne C., Goy A., et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995, 85(4):1083-1094.
26. Dong S., Tweardy D.J. Interactions of STAT5b-RARα, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002, 99(8):2637-2646.
27. Guidez F., Parks S., Wong H., et al. RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2007, 104(47):18694-18699.
28. Zhang X.W., Yan X.J., Zhou Z.R., et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 2010, 328(5975):240-243.
29. Such E., Cervera J., Valencia A., et al. A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 2011, 117(1):242-245.
30. Goyama S., Mulloy J.C. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol 2011, 94(2):126-133.
31. Martens J.H.A., Stunnenberg H.G. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 2010, 584(12):2662-2669.
32. De Braekeleer E., Férec C., De Braekeleer M. RUNX1 translocations in malignant hemopathies. Anticancer Res 2009, 29(4):1031-1037.
33. Guastadisegni M.C., Lonoce A., Impera L., et al. CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia. Leukemia 2010, 24(8):1516-1519.
34. Slovak M.L., Bedell V., Popplewell L., et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002, 33(4):379-394.
35. Ottone T., Hasan S.K., Montefusco E., et al. Identification of a potential " hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer 2009, 48(3):213-221.
36. Meyer C., Kowarz E., Hofmann J., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23(8):1490-1499.
37. Smith E., Lin C., Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev 2011, 25(7):661-672.
38. Rubnitz J.E., Raimondi S.C., Tong X., et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002, 20(9):2302-2309.
39. Mrózek K., Heinonen K., Lawrence D., et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood 1997, 90(11):4532-4538.
40. Beverloo H.B., Le Coniat M., Wijsman J., et al. Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis. Cancer Res 1995, 55(19):4220-4224.
41. Klaus M., Schnittger S., Haferlach T., et al. Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement. Cancer Genet Cytogenet 2003, 144(1):36-43.
42. Bloomfield C.D., Archer K.J., Mrózek K., et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33(4):362-378.
43. Felix C.A., Kolaris C.P., Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst) 2006, 5(9-10):1093-1108.
44. Soekarman D., von Lindern M., Daenen S., et al. The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 1992, 79(11):2990-2997.
45. Xu S., Powers M.A. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009, 20(5):620-630.
46. Secker-Walker L.M., Mehta A., Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995, 91(2):490-501.
47. Morishita K., Parker D.S., Mucenski M.L., et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54(6):831-840.
48. Du Y., Jenkins N.A., Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005, 106(12):3932-3939.
49. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16(2):198-204.
50. Mercher T., Le Coniat M.B., Monni R., et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A 2001, 98(10):5776-5779.
51. Ma Z., Morris S.W., Valentine V., et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001, 28(3):220-221.
52. Cheng E.-C., Luo Q., Bruscia E.M., et al. Role for MKL1 in megakaryocytic maturation. Blood 2009, 113(12):2826-2834.
53. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010, 116(3):354-365.
54. Mrózek K., Heinonen K., Theil K.S., et al. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes Cancer 2002, 34(2):137-153.
55. Galván A.B., Mallo M., Arenillas L., et al. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. Leuk Res 2010, 34(9):1242-1245.
56. Yoneda-Kato N., Look A.T., Kirstein M.N., et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996, 12(2):265-275.
57. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23(7):1252-1256.
58. Ebert B.L. Genetic deletions in AML and MDS. Best Pract Res Clin Haematol 2010, 23(4):457-461.
59. Mrózek K., Holland K.B., Pettenati M.J., et al. Prognostic significance of unbalanced chromosome abnormalities used by 2008 World Health Organization (WHO) classification to define " acute myeloid leukemia (AML) with myelodysplasia-related changes" in adults: a Cancer and Leukemia Group B (CALGB) study. Blood 2009, 114(22):1021. [abstract 2602].
60. Haematological Malignancy Research Network, University of York, United Kingdom. Available at: Accessed July 25, 2011. http://www.hmrn.org/Statistics/Incidence_Wizard.aspx.
61. Chessells J.M., Harrison C.J., Kempski H., et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia Working Party. Leukemia 2002, 16(5):776-784.
62. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
63. Schoch C., Haase D., Haferlach T., et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996, 10(8):1288-1295.
64. Byrd J.C., Mrózek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100(13):4325-4336.
65. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22(18):3741-3750.
66. Marcucci G., Mrózek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23(24):5705-5717.
67. Mrózek K., Prior T.W., Edwards C., et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2001, 19(9):2482-2492.
68. Mrózek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109(2):431-448.
69. Marcucci G., Haferlach T., Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29(5):475-486.
70. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92(7):2322-2333.
71. Cornelissen J.J., van Putten W.L.J., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109(9):3658-3666.
72. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301(22):2349-2361.
73. Care R.S., Valk P.J.M., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003, 121(5):775-777.
74. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006, 24(24):3904-3911.
75. Cuneo A., Ferrant A., Michaux J.L., et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996, 81(5):423-427.
76. Slovak M.L., Gundacker H., Bloomfield C.D., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20(7):1295-1297.
77. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335.
78. Breems D.A., Van Putten W.L.J., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26(29):4791-4797.
79. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 2008, 35(4):365-377.
80. Medeiros B.C., Othus M., Fang M., et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116(13):2224-2228.
81. Fang M., Storer B., Estey E., et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011, 118(6):1490-1494.
82. Raimondi S.C., Chang M.N., Ravindranath Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821. Blood 1999, 94(11):3707-3716.
83. von Neuhoff C., Reinhardt D., Sander A., et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010, 28(16):2682-2689.
84. Harrison C.J., Moorman A.V., Hills R.K., et al. Cytogenetics of childhood acute myeloid leukemia: 753 patients in UK Medical Research Council treatment trials, AML 10 and 12. J Clin Oncol 2010, 28(16):2674-2681.
85. Coenen E.A., Raimondi S.C., Harbott J., et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011, 117(26):7102-7111.
86. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98(5):1312-1320.
87. Farag S.S., Archer K.J., Mrózek K., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108(1):63-73.
88. Fröhling S., Schlenk R.F., Kayser S., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006, 108(10):3280-3288.
89. Schoch C., Haferlach T., Haase D., et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001, 112(1):118-126.
90. Farag S.S., Maharry K., Zhang M-J., et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients aged 60-70 years with acute myeloid leukemia in first remission. Biol Blood Marrow Transplant 2011, 10.1016/j.bbmt.2011.06.005.
91. Blum W., Garzon R., Klisovic R.B., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010, 107(16):7473-7478.
92. Perrot A., Luquet I., Pigneux A., et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011, 118(3):679-685.
93. Grimwade D. Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia 2002, 16(5):964-969.
94. Burnett A.K., Grimwade D., Solomon E., et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999, 93(12):4131-4143.
95. Sarriera J.E., Albitar M., Estrov Z., et al. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia 2001, 15(1):57-61.
96. Rücker F.G., Bullinger L., Gribov A., et al. Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. Genes Chromosomes Cancer 2011, 50(1):51-58.
97. Mrózek K., Carroll A.J., Maharry K., et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol 2008, 33(2):239-244.
98. Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111(8):4329-4337.
99. Hollink I.H.I.M., van den Heuvel-Eibrink M.M., Arentsen-Peters S.T.C.J.M., et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011, 118(13):3645-3656.
100. Walter M.J., Payton J.E., Ries R.E., et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009, 106(31):12950-12955.
101. Tiu R.V., Gondek L.P., O'Keefe C.L., et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27(31):5219-5226.
102. Bullinger L., Krönke J., Schön C., et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 2010, 24(2):438-449.
103. Parkin B., Erba H., Ouillette P., et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 2010, 116(23):4958-4967.
104. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009, 385-395.
105. Löwenberg B. Genetic markers in relation to the therapeutic management of acute myeloid leukemia. Hematology Education 2011, 5:36-41.
106. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10(12):1911-1918.
107. Kiyoi H., Naoe T., Yokota S., et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 1997, 11(9):1447-1452.
108. Kottaridis P.D., Gale R.E., Linch D.C. FLT3 mutations and leukaemia. Br J Haematol 2003, 122(4):523-538.
109. Whitman S.P., Archer K.J., Feng L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001, 61(19):7233-7239.
110. Fitzgibbon J., Smith L.L., Raghavan M., et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005, 65(20):9152-9154.
111. Paschka P., Marcucci G., Ruppert A.S., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26(28):4595-4602.
112. Virappane P., Gale R., Hills R., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26(33):5429-5435.
113. Renneville A., Boissel N., Zurawski V., et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009, 115(16):3719-3727.
114. Gaidzik V.I., Schlenk R.F., Moschny S., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113(19):4505-4511.
115. Tang J-L., Hou H-A., Chen C-Y., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114(26):5352-5361.
116. Schnittger S., Dicker F., Kern W., et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011, 117(8):2348-2357.
117. Gaidzik V.I., Bullinger L., Schlenk R.F., et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011, 29(10):1364-1372.
118. Caligiuri M.A., Strout M.P., Lawrence D., et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998, 58(1):55-59.
119. Schnittger S., Kinkelin U., Schoch C., et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000, 14(5):796-804.
120. Döhner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002, 20(15):3254-3261.
121. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1909-1918.
122. Whitman S.P., Ruppert A.S., Marcucci G., et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007, 109(12):5164-5167.
123. Pabst T., Mueller B.U., Zhang P., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet 2001, 27(3):263-270.
124. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352(3):254-266.
125. Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer 2004, 4(5):394-400.
126. Pabst T., Mueller B.U. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 2009, 15(17):5303-5307.
127. Smith M.L., Cavenagh J.D., Lister T.A., et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004, 351(23):2403-2407.
128. Pabst T., Eyholzer M., Haefliger S., et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008, 26(31):5088-5093.
129. Kirstetter P., Schuster M.B., Bereshchenko O., et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 2008, 13(4):299-310.
130. Bereshchenko O., Mancini E., Moore S., et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPα mutant AML. Cancer Cell 2009, 16(5):390-400.
131. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100(8):2717-2723.
132. Fröhling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22(4):624-633.
133. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26(31):5078-5087.
134. Wouters B.J., Löwenberg B., Erpelinck-Verschueren C.A.J., et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113(13):3088-3091.
135. Pabst T., Eyholzer M., Fos J., et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100(8):1343-1346.
136. Renneville A., Boissel N., Gachard N., et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009, 113(21):5090-5093.
137. Green C.L., Koo K.K., Hills R.K., et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28(16):2739-2747.
138. Taskesen E., Bullinger L., Corbacioglu A., et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011, 117(8):2469-2475.
139. Falini B. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features. Cancer Treat Res 2010, 145:149-168.
140. Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114(11):2220-2231.
141. Krönke J., Schlenk R.F., Jensen K-O., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011, 29(19):2709-2716.
142. Vassiliou G.S., Cooper J.L., Rad R., et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011, 43(5):470-475.
143. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106(12):3733-3739.
144. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106(12):3740-3746.
145. Verhaak R.G.W., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106(12):3747-3754.
146. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111(5):2776-2784.
147. Becker H., Marcucci G., Maharry K., et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(4):596-604.
148. Haferlach C., Mecucci C., Schnittger S., et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009, 114(14):3024-3032.
149. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
150. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433.
151. Marcucci G., Maharry K., Wu Y-Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(14):2348-2355.
152. Green C.L., Evans C.M., Zhao L., et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011, 118(2):409-412.
153. Boissel N., Nibourel O., Renneville A., et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011, 117(13):3696-3697.
154. Best T., Li D., Skol A.D., et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011, 17(8):941-943.
155. Link D.C., Schuettpelz L.G., Shen D., et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011, 305(15):1568-1576.
156. Marcucci G., Mrózek K., Radmacher M.D., et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011, 117(4):1121-1129.
157. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1919-1928.
158. Schwind S., Maharry K., Radmacher M.D., et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28(36):5257-5264.
159. Mohrin M., Bourke E., Alexander D., et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010, 7(2):174-185.
160. Milyavsky M., Gan O.I., Trottier M., et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010, 7(2):186-197.
161. Lovett B.D., Strumberg D., Blair I.A., et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry 2001, 40(5):1159-1170.
162. Mistry A.R., Felix C.A., Whitmarsh R.J., et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005, 352(15):1529-1538.
163. Hasan S.K., Mays A.N., Ottone T., et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008, 112(8):3383-3390.
164. Mays A.N., Osheroff N., Xiao Y., et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010, 115(2):326-330.
165. Alexander F.E., Patheal S.L., Biondi A., et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001, 61(6):2542-2546.
166. Hall G.W. Childhood myeloid leukaemias. Best Pract Res Clin Haematol 2001, 14(3):573-591.
167. Haffner M.C., Aryee M.J., Toubaji A., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010, 42(8):668-675.
168. Zuber J., Shi J., Wang E., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478(7370):524-528.
169. Dawson M.A., Prinjha R.K., Dittmann A., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478(7370):529-533.
170. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96(13):4075-4083.
171. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003, 102(4):1232-1240.
172. Schoch C., Schnittger S., Klaus M., et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102(7):2395-2402.